2014
DOI: 10.1177/1076029614522545 View full text |Buy / Rent full text
|
|

Abstract: In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 μg/kg, intravenously per week for 4 weeks, in a randomized fashion. The primary aim was to compare FVII:coagulation activity (FVII:C), 20 minutes after recombinant activated FVII (rFVIIa) injection, in the 2 groups. A secondary measure was self-reported bleeding. The median interquartile baseline range of the plasma level of activat… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
0
10
0

Publication Types

Select...

Relationship

0
0

Authors

Journals